INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2015

In Crohn's disease patients in remission, 2000 IU/day vitamin D for 3 months maintained intestinal permeability and increased cathelicidin levels.

Twenty-seven Crohn's disease patients in remission were assigned to 2000 IU/day vitamin D or placebo for 3 months. At 3 months, 25(OH)D levels were significantly higher in the treated group (p < 0.001), with increased LL-37 concentrations (p = 0.050) and maintenance of intestinal permeability, whereas placebo patients experienced increases in small bowel (p = 0.018) and gastro-duodenal permeability (p = 0.030). Patients reaching 25(OH)D ≥ 75 nmol/L at 3 months had significantly lower CRP (p = 0.019), higher Quality of Life (p = 0.037), and higher LL-37 concentrations (p < 0.001) compared to those with levels < 75 nmol/L.

Study type
Double-blind randomised placebo-controlled study
Who was studied
27 Crohn's disease patients in remission
What was measured
Intestinal permeability, cathelicidin (LL-37), hBD2, CDAI, CRP, fecal calprotectin, Quality of Life, and serum 25(OH)D

THE PAPER

Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn's disease: Results from a randomised double-blind placebo-controlled study.

Raftery T, Martineau AR, Greiller CL, Ghosh S, McNamara D, Bennett K, Meddings J, O'Sullivan M. United European Gastroenterol J, 2015.

PubMed 26137304 ↗DOI 10.1177/2050640615572176 ↗

Gut & microbiomeNutrients & adequacy

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.